Can-Fite BioPharma (CANF) Assets Average (2014 - 2025)
Can-Fite BioPharma's (CANF) quarterly Assets Average came in at $8.6 million in Q4 2025, up 14.57% YoY from $7.5 million in Q4 2024, and up 2.34% on a QoQ basis from $8.4 million in Q2 2025.
Can-Fite BioPharma (CANF) Assets Average (2014 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 12 years of Assets Average data on file, last reported at $8.6 million in Q4 2025.
- Quarterly Assets Average rose 14.57% year-over-year to $8.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.6 million (up 14.57% YoY) and the FY2025 annual result came in at $9.3 million, down 2.49% from the prior year.
- Assets Average rose to $8.6 million in Q4 2025, from $8.4 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $19.0 million in Q1 2022 to a low of $7.5 million in Q4 2024.
- A 5-year average of $11.7 million and a median of $11.2 million in 2021 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average soared 71.12% — and 2023, when it tumbled 40.23%.
- Tracing CANF's Assets Average over 5 years: stood at $17.4 million in 2021, then tumbled by 36.98% to $11.0 million in 2022, then fell by 12.87% to $9.6 million in 2023, then decreased by 21.48% to $7.5 million in 2024, then rose by 14.57% to $8.6 million in 2025.
- The last three Assets Average figures came in at $8.6 million (Q4 2025), $8.4 million (Q2 2025), and $7.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | 8.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.62 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Dec 31, 2024 | 7.52 Mn |
| Jun 30, 2024 | 7.96 Mn |
| Dec 31, 2023 | 9.58 Mn |
| Sep 30, 2023 | 10.10 Mn |
| Jun 30, 2023 | 12.26 Mn |
| Mar 31, 2023 | 11.39 Mn |
| Dec 31, 2022 | 10.99 Mn |
| Sep 30, 2022 | 13.73 Mn |
| Jun 30, 2022 | 16.30 Mn |
| Mar 31, 2022 | 19.05 Mn |
| Dec 31, 2021 | 17.45 Mn |
| Sep 30, 2021 | 12.16 Mn |
| Jun 30, 2021 | 11.21 Mn |
| Mar 31, 2021 | 11.13 Mn |
| Dec 31, 2020 | 11.42 Mn |
| Sep 30, 2020 | 13.06 Mn |
| Dec 31, 2019 | 9.96 Mn |
| Sep 30, 2019 | 12.71 Mn |